CAMBRIDGE, Mass., Nov. 14 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. , a biotechnology company developing drugs based on its proprietary sugar sequencing technology, today announced that it will be added to the NASDAQ Biotechnology Index(R) effective at the market open on Monday, November 21, 2005.
“We are honored to be selected to join the leading companies in the NASDAQ Biotechnology Index,” said Alan Crane, Chief Executive Officer of Momenta. “We believe that the inclusion of Momenta in this index is a validation of the advancement by our team of our development and discovery programs and their dedication to building value for our shareholders.”
Launched in 1993, the NASDAQ Biotechnology Index includes pharmaceutical and biotechnology companies as classified by the FTSE(TM) Global Classification System. The NASDAQ Biotechnology Index is ranked on a semi- annual basis in May and November. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ National Market and meet specific criteria, including market value, average daily share volume and seasoning as a public company. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.
About Momenta
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of sugar-based and complex drug products. The Company’s most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox(R). Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at http://www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Michael A. Lawless Momenta Pharmaceuticals, Inc. 617-395-5189
Momenta Pharmaceuticals, Inc.
CONTACT: Michael A. Lawless of Momenta Pharmaceuticals, Inc.,+1-617-395-5189
